Viridian Therapeutics financials
$20.00−2.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $284.0K | $141.0K | $132.0K | $70.6M | $75.0K | $72.0K | $72.0K | $86.0K | $72.0K | $72.0K | $72.0K | $72.0K |
| Gross profit | $284.0K | $141.0K | $132.0K | $70.6M | $75.0K | $72.0K | $72.0K | $86.0K | $72.0K | $72.0K | $72.0K | $72.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$126.3M | -$116.8M | -$122.7M | -$40.0M | -$106.8M | -$93.9M | -$87.5M | -$83.5M | -$72.2M | -$55.9M | -$71.5M | -$51.2M |
| Net income | -$112.8M | -$92.0M | -$101.1M | -$28.2M | -$82.0M | -$70.7M | -$64.5M | -$58.8M | -$49.5M | -$36.1M | -$4.1M | -$47.7M |
| Net margin | −39726.8% | −65266.7% | −76569.7% | −39.9% | −109304.0% | −98177.8% | −89530.6% | −68329.1% | −68684.7% | −50208.3% | −5740.3% | −66194.4% |
| Diluted EPS | $-1.05 | $-0.90 | $-1.07 | $-0.34 | $-1.00 | $-0.87 | $-0.80 | $-0.88 | $-0.77 | $-0.59 | $-0.08 | $-1.09 |
| EBITDA | -$126.2M | -$116.7M | -$122.6M | -$39.9M | -$106.7M | -$93.8M | -$87.3M | -$83.3M | -$72.0M | -$55.8M | -$71.5M | -$51.1M |
| Operating cash flow | -$105.3M | -$119.7M | -$23.8M | -$84.6M | -$75.4M | -$92.7M | -$73.3M | -$67.7M | -$46.1M | -$45.2M | -$38.0M | -$39.0M |
| Free cash flow | -$106.6M | -$119.7M | -$24.0M | -$84.7M | -$75.4M | -$92.7M | -$73.4M | -$68.0M | -$46.2M | -$45.2M | -$38.0M | -$39.4M |
| Diluted shares | 107.9M | 102.2M | 94.5M | 81.8M | 81.6M | 81.3M | 80.2M | 66.4M | 63.9M | 61.1M | 49.9M | 43.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $165.0M | $176.3M | $212.4M | $169.6M | $117.3M | $116.2M |
| Short-term investments | $816.5M | $585.8M | $662.3M | $321.3M | $446.0M | $520.4M |
| Total debt | $355.8M | $86.5M | $84.2M | $20.9M | $20.8M | $20.7M |
| Total assets | $1.10B | $789.0M | $899.4M | $577.1M | $582.3M | $661.0M |
| Total liabilities | $435.1M | $153.0M | $177.3M | $74.2M | $67.2M | $56.5M |
| Shareholders' equity | $662.1M | $636.0M | $722.2M | $503.0M | $515.2M | $604.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology